MARKET

BPTH

BPTH

Bio-Path Holdings
NASDAQ

Real-time Quotes | Nasdaq Last Sale

5.15
+0.02
+0.00%
Closed 16:00 07/07 EDT
OPEN
5.15
PREV CLOSE
5.15
HIGH
5.25
LOW
5.08
VOLUME
27.66K
TURNOVER
--
52 WEEK HIGH
17.53
52 WEEK LOW
2.920
MARKET CAP
19.01M
P/E (TTM)
-1.5642
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 1 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average BPTH stock price target is 18.00 with a high estimate of 18.00 and a low estimate of 18.00.

EPS

BPTH News

More
Edited Transcript of BPTH.OQ earnings conference call or presentation 15-May-20 12:30pm GMT
Thomson Reuters StreetEvents · 06/26 04:28
Bio-Path Holdings Presents at 2020 American Society of Clinical Oncology Annual Meeting
GlobeNewswire · 05/29 13:00
61 Biggest Movers From Yesterday
Gainers Nano Dimension Ltd. (NASDAQ: NNDM) shares surged 341.7% to close at $3.40 on Tuesday. HENSOLDT and Nano Dimension achieved a major breakthrough in electronics 3D printing.
Benzinga · 05/20 08:50
44 Stocks Moving In Tuesday's Mid-Day Session
Gainers Nano Dimension Ltd. (NASDAQ: NNDM) jumped 85.8% to $1.43. HENSOLDT and Nano Dimension achieved a major breakthrough in electronics 3D printing.
Benzinga · 05/19 16:48
HC Wainwright & Co. Reiterates Buy on Bio-Path Holdings, Lowers Price Target to $18
HC Wainwright & Co. reiterates Bio-Path Holdings (NASDAQ:BPTH) with a Buy and lowers the price target from $25 to $18.
Benzinga · 05/18 11:28
Bio-Path Holdings, Inc. (BPTH) CEO Peter Nielsen on Q1 2020 Results - Earnings Call Transcript
Seeking Alpha - Transcript · 05/15 16:21
Bio-Path Holdings Reports First Quarter 2020 Financial Results
GlobeNewswire · 05/15 12:00
The Daily Biotech Pulse: Co-Diagnostics Earnings, NantKwest Plans Pancreatic Cancer Study, ADC Therapeutics IPO
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 14)
Benzinga · 05/15 11:49

Industry

Biotechnology & Medical Research
+1.75%
Pharmaceuticals & Medical Research
-0.01%

Hot Stocks

Symbol
Price
%Change

About BPTH

Bio-Path Holdings, Inc. is a clinical and preclinical stage oncology focused antisense drug development company. The Company utilizes a technology that achieves systemic delivery for target specific protein inhibition for any gene product that is over-expressed in disease. The Company's drug delivery and antisense technology, called DNAbilize, is a platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification that is intended to protect the DNA from destruction by the body's enzymes when circulating in vivo, incorporated inside of a neutral charged lipid bilayer. In vivo, the DNAbilize delivered antisense drug substances are systemically distributed across the body to allow for reduction or elimination of proteins in blood diseases and solid organs. Using DNAbilize as a platform for drug manufacturing, the Company has approximately three antisense drug candidates in development to treat a total of over five different cancer disease indications.
More

Webull offers kinds of Bio-Path Holdings Inc stock information, including NASDAQ:BPTH real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BPTH stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading BPTH stock methods without spending real money on the virtual paper trading platform.